AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26341847 — intervention group
Group type: COMPARATOR
Intervention: Health behavior attention control brief intervention (AC)
Number of subjects: 33
Study 23756854 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 256
Study 23756854 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 256
Study 23756854 — intervention group
Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 256
Study 23756854 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsiveness
Number of subjects: 256
Study 22013492 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-target treatment (3T)
Number of subjects: 80
Study 22013492 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency stimulation (LFS)
Number of subjects: 80
Study 19643024 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood walking intervention
Number of subjects: 0
Study 17183987 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (unfractionated or low-molecular weight)
Number of subjects: 0
Study 17183987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 0
Study 12657165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen, given 6 times daily during 5 days
Number of subjects: 75
Study 12657165 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen, given 6 times daily during 5 days
Number of subjects: 75
Study 12657165 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given 6 times daily during 5 days
Number of subjects: 75
Study 12799920 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 9
Study 12799920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrazepam
Number of subjects: 9
Study 12799920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9064108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 26
Study 9064108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 120 mg
Number of subjects: 26
Study 9064108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg and 120 mg
Number of subjects: 26
Study 1722512 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral gold therapy
Number of subjects: 11
Study 1722512 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral gold therapy combined with 120 mg intramuscular methylprednisolone acetate at Weeks 0, 4 and 8
Number of subjects: 11
Study 1722512 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment mentioned)
Number of subjects: 11
Study 6357930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg three times daily
Number of subjects: 12
Study 6357930 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg four times daily
Number of subjects: 12
Study 31923736 — intervention group
Group type: EXPERIMENTAL
Intervention: PUQE-24 questionnaire scores at hospital admission
Number of subjects: 215
Study 31923736 — intervention group
Group type: EXPERIMENTAL
Intervention: NVPQoL questionnaire scores at hospital admission
Number of subjects: 215
Study 31923736 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change, total days of hospital admission, and readmission
Number of subjects: 215
Study 30586199 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF DPI
Number of subjects: 65
Study 30586199 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF pMDI
Number of subjects: 65
Study 30586199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 27639387 — intervention group
Group type: EXPERIMENTAL
Intervention: Acotiamide 100 mg × 3/day for 2 weeks
Number of subjects: 50
Study 27639387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27107325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-luteal phase surgical oophorectomy + oral tamoxifen
Number of subjects: 249
Study 27107325 — intervention group
Group type: COMPARATOR
Intervention: Mid-follicular phase surgical oophorectomy + oral tamoxifen
Number of subjects: 249
Study 27107325 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase surgery patients with progesterone levels <2 ng/ml
Number of subjects: 249
Study 27107325 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase surgery patients with progesterone levels ≥2 ng/ml
Number of subjects: 249
Study 24656301 — intervention group
Group type: COMPARATOR
Intervention: One fluoroscope
Number of subjects: 27
Study 24656301 — intervention group
Group type: EXPERIMENTAL
Intervention: Two fluoroscopes
Number of subjects: 27
Study 21733056 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate 100 mg BID
Number of subjects: 35
Study 21733056 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate 1000 mg QD
Number of subjects: 35
Study 21733056 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate 1000 mg BID
Number of subjects: 35
Study 21733056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19664258 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (surgical reconstruction)
Number of subjects: 34
Study 19664258 — intervention group
Group type: COMPARATOR
Intervention: Training only
Number of subjects: 34
Study 17478452 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. sufentanil 2.5 microg
Number of subjects: 90
Study 17478452 — intervention group
Group type: EXPERIMENTAL
Intervention: IT sufentanil 2.5 microg
Number of subjects: 90
Study 17478452 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine alone
Number of subjects: 90
Study 15774786 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of cyclophosphamide, doxorubicin, methotrexate, fluorouracil, and prednisone (CAMFP) before RT (CT-first)
Number of subjects: 244
Study 15774786 — intervention group
Group type: COMPARATOR
Intervention: RT-first (radiation therapy before chemotherapy)
Number of subjects: 244
Study 11753001 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-rubber catheter-guided nasotracheal intubation
Number of subjects: 0
Study 11753001 — intervention group
Group type: COMPARATOR
Intervention: Nasotracheal tube alone inserted (control group)
Number of subjects: 0
Study 9549922 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pidolate supplementation at 0.6 mEq/kg/day for four weeks
Number of subjects: 11
Study 9549922 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pidolate supplementation at 1.2 mEq/kg/day for an additional four weeks
Number of subjects: 11
Study 9549922 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (17 subjects)
Number of subjects: 11
Study 9549922 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with beta thalassemia intermedia (11 subjects)
Number of subjects: 11
Study 7932344 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmarch bandages
Number of subjects: 100
Study 7932344 — intervention group
Group type: COMPARATOR
Intervention: Simple elevation for 2 min
Number of subjects: 100
Study 3144330 — intervention group
Group type: EXPERIMENTAL
Intervention: Four layer bandage system
Number of subjects: 126
Study 3144330 — intervention group
Group type: COMPARATOR
Intervention: Traditional adhesive plaster bandaging
Number of subjects: 126
Study 31680023 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy (MBT) for PNES, 12 sessions
Number of subjects: 49
Study 30657649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold knife
Number of subjects: 22
Study 30657649 — intervention group
Group type: COMPARATOR
Intervention: Monopolar cautery
Number of subjects: 22
Study 28278021 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (N = 12)
Number of subjects: 24
Study 28278021 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 12)
Number of subjects: 24
Study 25829422 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive iPad program (IP)
Number of subjects: 283
Study 25829422 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper format (TF)
Number of subjects: 283
Study 24104532 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with 15 mg 0.5% hyperbaric bupivacaine intrathecally
Number of subjects: 50
Study 24104532 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliohypogastric ilioinguinal nerve block (IHNB) with 20 mL 0.5% plain bupivacaine
Number of subjects: 50
Study 21890825 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention (2 to 3 consultations covering behavioral sleep strategies)
Number of subjects: 108
Study 21890825 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Number of subjects: 108
Study 21890825 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 19220559 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention (3-day educational program on depression)
Number of subjects: 1914
Study 19220559 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (generic course on disease management in elderly people)
Number of subjects: 1914
Study 17686670 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity walking (above 115% of VT or 74% of VO2 max, speeds above 6.14 km/h, mechanical loading of 872.3 N)
Number of subjects: 43
Study 17686670 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity walking (below 115% of VT or 74% of VO2 max)
Number of subjects: 43
Study 17686670 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity walking
Number of subjects: 43
Study 15076221 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily
Number of subjects: 24
Study 15076221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11384804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily for 6 months)
Number of subjects: 20
Study 11384804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9402540 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial meningitis (n = 16)
Number of subjects: 44
Study 9402540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aseptic meningitis (n = 12)
Number of subjects: 44
Study 9402540 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 16)
Number of subjects: 44
Study 8357888 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use (including prescription and nonprescription)
Number of subjects: 178
Study 8357888 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple medication use
Number of subjects: 178
Study 8357888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprescription medication use
Number of subjects: 178
Study 8357888 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and compliance with medication
Number of subjects: 178
Study 8357888 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple medication use and wellbeing
Number of subjects: 178
Study 8357888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning
Number of subjects: 178
Study 8357888 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 178
Study 3620848 — intervention group
Group type: EXPERIMENTAL
Intervention: Large catheter assembly (4 and 10 F)
Number of subjects: 30
Study 3620848 — intervention group
Group type: COMPARATOR
Intervention: Small catheter assembly (epidural line, outside diameter 1.1 mm)
Number of subjects: 30
Study 3620848 — intervention group
Group type: EXPERIMENTAL
Intervention: Large catheter assembly (4 and 10 F) before prostatectomy
Number of subjects: 30
Study 3620848 — intervention group
Group type: COMPARATOR
Intervention: Small catheter assembly (epidural line, outside diameter 1.1 mm) before prostatectomy
Number of subjects: 30
Study 2783076 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year exercise program
Number of subjects: 79
Study 2783076 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control condition
Number of subjects: 79
Study 31801597 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy maintained before surgery
Number of subjects: 96
Study 31801597 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant therapy interrupted and substituted with subcutaneous heparin
Number of subjects: 96
Study 28932091 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-time split dose regimen
Number of subjects: 204
Study 28932091 — intervention group
Group type: COMPARATOR
Intervention: Split dose regimen
Number of subjects: 204
Study 26231300 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal total-etch
Number of subjects: 37
Study 26231300 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal self-etch
Number of subjects: 37
Study 26231300 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond Multi-purpose
Number of subjects: 37
Study 26231300 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal self-etch and Scotchbond Multi-purpose
Number of subjects: 37
Study 26231300 — intervention group
Group type: EXPERIMENTAL
Intervention: All adhesive materials
Number of subjects: 37
Study 23432209 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-Intensity Conditioning (RIC)
Number of subjects: 37
Study 23432209 — intervention group
Group type: COMPARATOR
Intervention: Myeloablative Conditioning (MAC)
Number of subjects: 37
Study 23432209 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RIC and MAC
Number of subjects: 37
Study 21272401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground hazelnuts (30 g/d)
Number of subjects: 48
Study 21272401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliced hazelnuts (30 g/d)
Number of subjects: 48
Study 21272401 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole hazelnuts (30 g/d)
Number of subjects: 48
Study 19798037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 298
Study 19798037 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 298
Study 17074626 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Tech-VR helmet (60-degree field-of-view head-mounted display)
Number of subjects: 77
Study 17074626 — intervention group
Group type: COMPARATOR
Intervention: Low-Tech-VR helmet (35-degree field-of-view head-mounted display)
Number of subjects: 77
Study 15636254 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of iodine (3-4 times a day as eye drops)
Number of subjects: 360
Study 15636254 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 360
Study 11776280 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0
Study 11776280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9142433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 2.5 mg single oral dose
Number of subjects: 241
Study 9142433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 5.0 mg single oral dose
Number of subjects: 241
Study 9142433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 2.5 mg b.i.d. for 8 weeks
Number of subjects: 241
Study 9142433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan 1.25 mg and 2.5 mg b.i.d. long-term treatment
Number of subjects: 241
Study 9142433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 10155593 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim
Number of subjects: 120
Study 3297914 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-K Extencaps
Number of subjects: 0
Study 3297914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ethyl cellulose)
Number of subjects: 0
Study 29672526 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted handoff intervention (education session, standardized procedures, fixed time and location for handoff)
Number of subjects: 18
Study 29672526 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted handoff intervention
Number of subjects: 18
Study 29672526 — intervention group
Group type: COMPARATOR
Intervention: Usual non-standardized handoffs (control group)
Number of subjects: 18
Study 27806235 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 10‐2474 (50 mg per day)
Number of subjects: 6
Study 27806235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 24496169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 μg/mL
Number of subjects: 52
Study 22214842 — intervention group
Group type: EXPERIMENTAL
Intervention: LCn‐3PUFA (fish oil group)
Number of subjects: 32
Study 22214842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (monounsaturated oil group)
Number of subjects: 32
Study 19859755 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of background exposure to a novel domain
Number of subjects: 0
Study 19859755 — intervention group
Group type: COMPARATOR
Intervention: Evaluative tasks
Number of subjects: 0
Study 17417075 — intervention group
Group type: COMPARATOR
Intervention: Halofantrine (HF) 500 mg alone
Number of subjects: 10
Study 17417075 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (HF) 500 mg with prior administration of amodiaquine (AQ) 600 mg
Number of subjects: 10
Study 16311142 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (20 mg/day)
Number of subjects: 38
Study 16311142 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (120 mg/day)
Number of subjects: 38
Study 12730556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg/d
Number of subjects: 20
Study 12730556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10551579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 10 microg
Number of subjects: 106
Study 10551579 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal sufentanil alone (ED50 4.1 +/- 0.31 microg)
Number of subjects: 106
Study 10551579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil combined with neostigmine 10 microg (ED50 3.0 +/- 0.28 microg)
Number of subjects: 106
Study 10551579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (9 microg)
Number of subjects: 106
Study 10551579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (6 microg) plus neostigmine (10 microg)
Number of subjects: 106
Study 7551923 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy
Number of subjects: 700
Study 7551923 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 700
Study 2025853 — intervention group
Group type: EXPERIMENTAL
Intervention: 4250 cGy in 25 daily fractions for 5 weeks (Group 1)
Number of subjects: 86
Study 2025853 — intervention group
Group type: EXPERIMENTAL
Intervention: 4500 cGy in 25 daily fractions for 5 weeks (Group 2)
Number of subjects: 86
Study 2025853 — intervention group
Group type: EXPERIMENTAL
Intervention: 5100 cGy in 30 daily fractions for 6 weeks (Group 3)
Number of subjects: 86
Study 2025853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal brachytherapy after whole‐pelvis RT
Number of subjects: 86
Study 2025853 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth of myometrial invasion
Number of subjects: 86
Study 2025853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor grade, pathologic stage, whole‐pelvis radiation dose, and the use of brachytherapy
Number of subjects: 86
Study 6896576 — intervention group
Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 42
Study 6896576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30958353 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Cycloserine (DCS) 15 mg BID
Number of subjects: 756
Study 30958353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 756
Study 29253346 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 180
Study 29253346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 180
Study 29253346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 180
Study 26683109 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 2 mg q3h
Number of subjects: 339
Study 26683109 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 3 mg q3h
Number of subjects: 339
Study 26683109 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 4 mg q4h
Number of subjects: 339
Study 26683109 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 2 mg
Number of subjects: 339
Study 26683109 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV130 3 mg
Number of subjects: 339
Study 26683109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 26683109 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 339
Study 25253016 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic plasma
Number of subjects: 24
Study 25253016 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 24
Study 25253016 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylated gelatin
Number of subjects: 24
Study 25253016 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkland
Number of subjects: 24
Study 22395582 — intervention group
Group type: EXPERIMENTAL
Intervention: CT gel (clindamycin phosphate 1.2% and tretinoin 0.025%)
Number of subjects: 1649
Study 22395582 — intervention group
Group type: EXPERIMENTAL
Intervention: CT gel
Number of subjects: 1649
Study 22395582 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 1649
Study 22395582 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin
Number of subjects: 1649
Study 22395582 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 1649
Study 18469161 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic index (GI) and glycemic load (GL) dietary intervention for 9 weeks
Number of subjects: 103
Study 18469161 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group
Number of subjects: 103
Study 18469161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education regarding GI and GL
Number of subjects: 103
Study 17449506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium reduction for 18 months (TOHP I) or 36-48 months (TOHP II)
Number of subjects: 3126
Study 15776198 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 nm wavelength red diode laser
Number of subjects: 40